Georgette Tanner
YOU?
Author Swipe
View article: GBMPurity: A machine learning tool for estimating glioblastoma tumor purity from bulk RNA-sequencing data
GBMPurity: A machine learning tool for estimating glioblastoma tumor purity from bulk RNA-sequencing data Open
Background Glioblastoma (GBM) presents a significant clinical challenge due to its aggressive nature and extensive heterogeneity. Tumor purity, the proportion of malignant cells within a tumor, is an important covariate for understanding t…
View article: GBMPurity: A Machine Learning Tool for Estimating Glioblastoma Tumour Purity from Bulk RNA-seq Data
GBMPurity: A Machine Learning Tool for Estimating Glioblastoma Tumour Purity from Bulk RNA-seq Data Open
Background Glioblastoma (GBM) presents a significant clinical challenge due to its aggressive nature and extensive heterogeneity. Tumour purity, the proportion of malignant cells within a tumour, is an important covariate for understanding…
View article: Single-cell nanobiopsy enables multigenerational longitudinal transcriptomics of cancer cells
Single-cell nanobiopsy enables multigenerational longitudinal transcriptomics of cancer cells Open
Single-cell RNA sequencing has revolutionized our understanding of cellular heterogeneity, but routine methods require cell lysis and fail to probe the dynamic trajectories responsible for cellular state transitions, which can only be infe…
View article: LONGITUDINAL WGS AND WES OF GLIOBLASTOMA REVEAL POTENTIAL PATHWAY TARGETS
LONGITUDINAL WGS AND WES OF GLIOBLASTOMA REVEAL POTENTIAL PATHWAY TARGETS Open
AIMS Treating glioblastoma (GBM) patients remains challenging as the current regimens result in the recurrence of a treatment-resistant and fatal tumour. We aimed to identify candidate pathways that, when mutated, confer treatment resistan…
View article: PREDICTING GLIOBLASTOMA GENE EXPRESSION THERAPY RESPONSE WITH MACHINE LEARNING
PREDICTING GLIOBLASTOMA GENE EXPRESSION THERAPY RESPONSE WITH MACHINE LEARNING Open
AIMS The rapid recurrence of therapy-resistant glioblastoma leaves patients with a dismal 2-year survival rate of just 16%, highlighting the need to develop treatments that combat or prevent glioblastoma recurrence. Recently, glioblastoma …
View article: Single Cell Track and Trace: live cell labelling and temporal transcriptomics via nanobiopsy
Single Cell Track and Trace: live cell labelling and temporal transcriptomics via nanobiopsy Open
Single-cell RNA sequencing has revolutionised our understanding of cellular heterogeneity, but whether using isolated cells or more recent spatial transcriptomics approaches, these methods require isolation and lysis of the cell under inve…
View article: IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy
IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy Open
Glioblastoma (GBM) brain tumours lacking IDH1 mutations (IDHwt) have the worst prognosis of all brain neoplasms. Patients receive surgery and chemoradiotherapy but tumours almost always fatally recur. Using RNAseq data from 107 pairs of pr…
View article: IDHwt Glioblastomas Show Opposing Resistance Mechanisms Across Patients in Response to Standard Treatment
IDHwt Glioblastomas Show Opposing Resistance Mechanisms Across Patients in Response to Standard Treatment Open
AIMS Glioblastoma (GBM) is the most common primary malignant brain tumour in adults. Despite aggressive treatment, a resistant tumour recurs in practically all patients. We therefore aimed to better understand the mechanisms driving this t…
View article: Investigating intratumour heterogeneity analysis methods and their application in GBM
Investigating intratumour heterogeneity analysis methods and their application in GBM Open
Glioblastoma (GBM) is an incurable cancer with a median survival of 15 months. Despite debulking surgery, cancer cells are inevitably left behind in the surrounding brain, with a minority able to resist subsequent chemoradiotherapy and eve…
View article: GENE-28. LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS
GENE-28. LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS Open
Treatment options for adult patients with glioma has remained largely unchanged over the past three decades. Targeted inhibitors and immunotherapies have improved outcomes for many cancer types but their relevance in glioma is unclear. The…
View article: JARID2 facilitates transcriptional reprogramming in glioblastoma in response to standard treatment
JARID2 facilitates transcriptional reprogramming in glioblastoma in response to standard treatment Open
Background Glioblastoma (GBM) is a fatal and incurable brain cancer with a dismal prognosis. In order to impact on this disease, we need to understand how infiltrating, non resectable tumour cells resist chemoradiation and facilitate disea…
View article: Simulation of heterogeneous tumour genomes with HeteroGenesis and <i>in silico</i> whole exome sequencing
Simulation of heterogeneous tumour genomes with HeteroGenesis and <i>in silico</i> whole exome sequencing Open
Summary Tumour evolution results in progressive cancer phenotypes such as metastatic spread and treatment resistance. To better treat cancers, we must characterize tumour evolution and the genetic events that confer progressive phenotypes.…
View article: How to analyse the spatiotemporal tumour samples needed to investigate cancer evolution: A case study using paired primary and recurrent glioblastoma
How to analyse the spatiotemporal tumour samples needed to investigate cancer evolution: A case study using paired primary and recurrent glioblastoma Open
Many traits of cancer progression (e.g., development of metastases or resistance to therapy) are facilitated by tumour evolution: Darwinian selection of subclones with distinct genotypes or phenotypes that enable such progression. Characte…